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Pilot Study of Injection of OnabotulinumtoxinA Toward 
the Sphenopalatine Ganglion for the Treatment of Classical 
Trigeminal Neuralgia
Joan Crespi, MD; Daniel Bratbak, PhD; David W. Dodick, MD; Manjit Matharu, MD; Kent Are Jamtøy, MD;  
Erling Tronvik, PhD
Background.—The sphenopalatine ganglion (SPG) has previously been targeted in trigeminal neuralgia (TN), but its role 
in this condition has not been established.
Objective.—To investigate the safety of injecting onabotulinumtoxinA (BTA) toward the SPG using the MultiGuide® in 
10 patients with refractory classical TN, and collect preliminary efficacy data.
Methods.—Twenty-five international units (IU) of BTA were injected toward the SPG in a prospective, open-label study 
in 10 patients with refractory classical TN. All patients were recruited and treated on an out-patient basis at St. Olav’s 
University Hospital in Trondheim (Norway). Primary outcome: adverse events (AEs). Primary efficacy outcome: number of 
TN attacks at weeks 5-8 after injection compared to baseline. A treatment responder was predefined as at least 50% reduc-
tion in the median number of attacks per day between baseline and weeks 5-8. Other efficacy outcomes were intensity of 
attacks (numeric rating scale, 0 to 10) and functional level (1 to 4; 1 best and 4 worst) at weeks 5-8 after injection compared 
to baseline. Percentage of the day with concomitant persistent pain was registered at baseline and at weeks 1-4, 6, 8, and 
12 after injection. Patient global impression of change (PGIC) was ascertained at month 3.
Results.—For the primary endpoint, we analyzed data for all 10 patients. For efficacy outcomes we analyzed data for 
9 patients (1 patient violated protocol). We registered 13 AEs, none of which were serious. The median number of TN at-
tacks during the 4-week baseline and weeks 5-8 after injection was 5.5 (range: 1.0-51.5) and 5 (range: 0-225.0), respectively 
(P  =  .401). Four patients were treatment responders. The median intensity of attacks at baseline and weeks 5-8 after injec-
tion was 6 (range: 3.0-8.5) and 3 (range: 0.0-9.0) respectively (P  =  .024). The median functional level at baseline was 2 
(range: 1.0-3.3) and at month 2, 1 (range 1.0-4.0; P  =  .750). Median percentage of the day with concomitant persistent pain 
was 75% (minimum 37.5%, maximum 100%) at baseline and 18.75% (minimum 0%, maximum 100%) at week 8 (P  =  .023).
Conclusions.—Injection of BTA toward the SPG using the MultiGuide® in patients with TN appears to be safe and well 
tolerated. This study was negative for the main efficacy endpoint (reduction in the number of attacks from baseline to weeks 
5-8). Further studies examining the role of the SPG in TN are necessary.
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INTRODUCTION
Classical trigeminal neuralgia (TN) is defined as 
recurrent paroxysms of unilateral facial pain.1 The 
etiology of classical TN has been researched exten-
sively, but the exact pathophysiological processes 
leading to pain are not fully understood. Central to 
the pathogenesis seems to be a neurovascular con-
tact,2 but there is also evidence of the involvement of 
central pain mechanisms.3,4 Patients with TN often 
have a refractory period and this well-documented 
clinical feature suggests a central mechanism.3,5
In a prospective series of 158 patients with classi-
cal TN, 31% had autonomic symptoms.6 These symp-
toms included conjunctival injection and tearing, 
rhinorrhea, and nasal congestion.6 These symptoms 
may reflect activation of cranial parasympathetic 
 efferents from the sphenopalatine ganglion (SPG).7,8
The SPG may be involved in pain sensitization 
and it has been suggested that parasympathetic out-
flow contributes to pain by activating or sensitiz-
ing intracranial nociceptors.9 In the same series of 
158 patients with TN cited above, it was observed 
that 78 patients (49%) had concomitant persistent 
pain.6 Central facilitation of trigeminal nociceptive 
processing has been described in patients with TN 
with concomitant persistent facial pain.4
Treatment of TN includes both pharmacologi-
cal and surgical treatments.10 The role of the SPG in 
the pathogenesis of TN is not clear and high-quality 
randomized controlled trials (RCTs) have not been 
performed. Studies attempting to block the SPG in 
TN have been summarized in the literature.11,12 The 
overall grade of recommendation for SPG block in 
TN is grade B.11 In the only RCT conducted in TN at-
tempting to block the SPG, 25 patients were random-
ized to be treated with either intranasal lidocaine 8% 
or placebo for second-division TN.13 The lidocaine 
group had prompt but temporary analgesia. It should 
be noted that intranasal injection of drugs has not 
been proven to achieve blockade of the SPG and that 
proper blinding of intranasal local anesthetics may 
not have been achieved.14 Other authors have also tar-
geted the SPG in TN with varying results.15-22
Parasympathetic fibers synapse in the SPG using 
acetylcholine as neurotransmitter.7 onabotulinum-
toxinA (BTA) blocks the release of acetylcholine and 
2 pilot trials have examined the safety of injections 
of BTA toward the SPG in patients with intractable 
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chronic cluster headache and intractable chronic 
migraine.23,24
Given the reports suggesting that the SPG may 
be a viable therapeutic target for trigeminal pain 
syndromes, including TN, and that blockade of the 
SPG with BTA may be an effective intervention, we 
decided to examine the safety of injections with BTA 
toward the SPG in patients with classical TN using a 
new navigation device (the MultiGuide®) and to col-
lect pilot data on efficacy to inform and power future 
potential RCTs.
METHOD
Study Design and Participants.—A total of 10 
patients with classical TN (ICDH-3 Beta criteria) 
were recruited and treated between September 
2015 and October 2018 at St. Olav’s University 
Hospital, Trondheim, Norway. There was a baseline 
registration of 1 month previous to injection and the 
follow up was 3 months. One study month equaled 
28 days.
Table 1 shows inclusion and exclusion criteria.
All 10 patients were examined by a neurologist 
and CT and MRI scans of the sphenopalatine fossa 
were obtained before injection. Patients had to keep 
a daily diary 4 weeks prior to and for 3 months after 
the injection recording adverse events (AEs), num-
ber of TN attacks, intensity (using a numeric rating 
scale [NRS] from 0 to 10) and functional level (“how 
much of your planned activities for the day did you 
manage to complete”: 1: all; 2: more than 50%; 3: less 
than 50%; 4: none). Patients were instructed to count 
each paroxysm as an attack. The intensity level was 
recorded as an average of the individual paroxysms 
through 1 day.
Description of the Procedure.—Our research group 
has developed a novel injection device to perform 
surgical navigation-assisted administration of BTA 
toward the SPG (the MultiGuide®, Fig. 1) ipsilateral 
to the pain. A single treatment was performed on 
an awake participant, using local anesthesia, in an 
outpatient office-based setting using a percutaneous, 
infrazygomatic approach using the MultiGuide®, 
aided by surgical navigation (Brainlab Kick version 1, 
Brainlab AG, Feldkirchen, Germany). Surgical 
navigation is a system that tracks and displays the tip of 
an instrument relative to a pre-acquired medical image. 
MultiGuide® enables the use of surgical navigation 
for high-precision injections on awake individuals and 
it enables repeated treatments without acquiring new 
CT and/or MRI for better radiation hygiene and 
lower cost. Pre-treatment planning of CT and MRI 
was performed with Brainlab iPlan 3.0 (Brainlab AG, 
Feldkirchen, Germany). The SPG ipsilateral to the 
pain was localized visually and marked on fused 
MRI and CT scans. With the patient in a supine 
Table 1.—Inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
• Willing to sign informed consent
• Age 18 to 80
• Classic TN according to ICHD-3b
• Unsatisfactory effect, intolerable side effects or contrain-
dications of one of the following:
○ Carbamazepine
○ Oxcarbazepine
And at least one of the following drugs:
○ Gabapentin
○ Pregabalin
○ Baclofen
○ Lamotrigine
○ Phenytoin
• Microvascular decompression is considered a better thera-
peutic choice
• Secondary TN
• Systemic or local disease that can interfere with the 
treatment
• Bilateral TN
• Reduced capacity to give informed consent
• Psychiatric condition preventing full participation
• Pregnancy or nursing
• Inability to use appropriate contraceptives in fertile women
• Abuse of drugs, including alcohol
• Anatomic anomalies that can hinder or impede treatment
• Hypersensitivity to local anesthetics, adrenalin or BTA or con-
comitant treatment with drugs that might interact with BTA
BTA = botulinum toxin type A; ICHD-3b = International Classification of Headache Disorders, 3 beta edition; TN = trigeminal 
neuralgia.
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position, the skin and deep structures toward the 
sphenopalatine fossa were anesthetized with 5-7  ml 
Marcaine-Adrenalin (5 mg/ml-5 µg/ml, AstraZeneca, 
Oslo, Norway) and a 1-2mm skin incision was made. 
Aided by surgical navigation and the MultiGuide®, 25 
international units BTA suspended in 0.5 ml isotonic 
saline was injected toward the SPG ipsilateral 
to the pain. The estimated duration of the injection 
is around 3 minutes, and for the whole procedure 
including navigation system setup 20-30 minutes. In 
this study, we used the same injection technique as in 
pilot trials in intractable chronic cluster headache and 
intractable chronic migraine.23,24
Outcome and Statistical Analysis.—The primary 
outcome was occurrence of AEs. All medical 
complications that participants experienced 
after the injection during the 3-month follow-up were 
evaluated as a possible AE. Information for possible 
AEs was collected from each telephone consultation 
(at weeks 1-4, 6, and 8 after injection), at last visit 
(month 3 after injection) and in the headache diaries 
(each day had a free text box for AEs). All health 
complaints (also those not requiring further medical 
intervention) were evaluated as a possible AEs and 
where in doubt, they were coded as AEs. The main 
efficacy outcome was number of TN attacks at 
weeks 5-8 after injection compared to baseline. 
Efficacy outcomes were measured at weeks 5-8 
(predefined in protocol) since onset of efficacy may 
require up to 4 weeks and maximal benefit would be 
expected during month 2 prior to the eventual and 
usual attenuation of the therapeutic effect of BTA 
during the 3rd month after injection. A treatment 
responder was predefined as at least 50% reduction 
in the median number of attacks per day between 
baseline and weeks 5-8. Other efficacy outcomes were 
intensity of the attacks, functional level at weeks 5-8 
after injection compared to baseline, Patient Global 
Impression of Change (PGIC) and percentage of the 
day with concomitant persistent pain.
PGIC was used to record patient’s assessment of 
the change in overall status according to a 7-point 
NRS (1: very much improved, 2: much improved, 
3: minimally improved, 4: no change, 5: minimally 
worse, 6: much worse, and 7 very much worse) at 
month 3 after injection.
Patients were asked to record the percentage of 
the day with concomitant persistent pain at baseline 
and weeks 1-4, 6, 8, and 12 after injection. The per-
centage of the day with concomitant persistent pain 
was stratified as 0%, 1 to 24%, 25 to 49%, 50 to 74%, 
75 to 99%, and 100%. A Friedman test (non-parametric 
Fig. 1.—The MultiGuide, a novel injection device to perform surgical navigation-assisted administration of botulinum toxin 
toward the sphenopalatine ganglion.
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analysis for repeated measurements) was performed. 
A Wilcoxon rank-sum exact test was used to analyze 
changes at weeks 1-4, 6, 8, and 12 after injection com-
pared to baseline.
A scale developed to screen for cranial parasym-
pathetic symptoms (CAPS scale25) was administered 
at baseline and 3 months after injection.
For the primary endpoint, we analyzed data for 
all 10 patients. A protocol violator was defined as 
a participant with less than 60% of diary days reg-
istered or change of prophylactic medication during 
the study. Missing values were estimated using the 
last observation carried forward methodology. For 
efficacy outcomes, we analyzed data for 9 patients 
(one patient was considered a protocol violator due to 
failure to count the number of attacks and document 
their intensity).
The study protocol was approved by the re-
gional ethical committee (REK 2015/1193) and the 
Norwegian Medicines Agency. All participants 
signed a written informed consent. This trial received 
the EUDRACT number: 2015-002643-33 and was reg-
istered at ClinicalTrial.gov (NCT02662972).
SPSS version 25.0 (SPSS Inc, Chicago, IL, USA) 
was used in the data analyses. For efficacy measures, 
we used the Wilcoxon signed rank test, and 2-sided 
P  <  .05 was considered statistically significant. A 
Friedman test for repeated measurements was per-
formed to analyze changes in the percentage of the day 
with concomitant persistent pain. Results are given as 
median and range. Means (±SD) were calculated in 
order to produce comparable results to other studies 
targeting the SPG using the same technique.23,24
Since the study is an exploratory safety study, no 
power calculation was performed prior to study start.
RESULTS
A total of 12 patients were screened. Two pa-
tients were considered screening failures during base-
line (one due to MRI findings of a brain stem lesion 
likely causing TN and the other did not feel impacted 
enough to undergo the study procedure). About 10 
patients (3 women and 7 men) completed the study, 
1 patient was a protocol violator and efficacy data 
could not be obtained for this patient. See Table 2 for 
demographics of the sample.
Table 3 summarizes the drugs currently used or 
previously tried by the 10 patients. The patients had 
been treated with a mean of 3.3 evidence-based med-
ications (minimum of 2 and maximum of 6 medica-
tions) prior to inclusion in this trial.
Three patients had previously undergone micro-
vascular decompression, 1 patient had previously 
tried glycerol rhizolysis of the trigeminal ganglion, 
and 1 patient had undergone balloon-compression of 
the trigeminal ganglion.
Table 2.—Demographics of the Sample
Demographics of the sample
Number of screened patients 12
Number of included patients 10
Number of females/males 3/7
Mean age, years ± SD (range) 59.4 ± 11.77 (39-74)
Mean years with trigeminal neuralgia  
± SD (range)
8.3 ± 8.6 (1.5-29)
Number of Caucasians 10/10
Side left/right 6/4
Hyperesthesia (in the trigeminal territory) 3/10
Allodynia (in the trigeminal territory) 2/10
Branches affected
V1 7/10
V2 10/10
V3 9/10
Previous history of stroke 4/10
Previous history of ischemic heart disease 2/10
Previous history of hypertension 3/10
Previous history of depression 2/10
SD  =  standard deviation; V1  =  ophthalmic nerve; 
V2 = maxillary nerve; V3 = mandibular nerve.
Table 3.—Drugs Used by the Participants of the Study
Drug
Number of Patients (n = 10)
Current Use Previous Use Not Tried
Carbamazepine 3 5 2
Oxcarbazepine 3 2 5
Gabapentine 1 9 0
Pregabaline 2 3 5
Baclofen 0 3 7
Lamotrigin 0 1 9
Fosphenytoin 0 1 9
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Primary Outcome (Safety).—Six out of 10 patients 
experienced AEs, none were serious (Table 4). All 
AEs were considered to be mild except for 1 patient 
who experienced diplopia moderately affecting 
his daily activities. This was assumed to be due to 
diffusion of BTA through the inferior orbital fissure 
which clinically produced a moderate paralysis of the 
inferior rectus muscle with hypertropia in abduction. 
The symptoms slowly improved and resolved 1 
month after conclusion of the study. This patient 
had a remarkably narrow sphenopalatine fossa. We 
believe that this anatomical characteristic played an 
important role on the development of this AE and this 
will be taken into consideration for further injections 
in similar patients.
Two patients experienced mild nasolabial fold 
asymmetry assumed to have been caused by diffusion 
of botulinum toxin toward the zygomatic muscles. 
Both patients reported that the slight asymmetry was 
not bothersome and resolved within 1 month after the 
study ended.
One patient experienced mild dysphagia (approx-
imately 2 weeks after injection, it was slightly harder 
to swallow phlegm, but he did not have dyspha-
gia when drinking or eating). This resolved within 
1 month after injection.
Three patients had mild pain or swelling at the 
injection side that resolved in all cases within the first 
month after injection. Just 1 of the patients had to 
take additional analgesics on the day of injection.
Four patients reported mild discomfort in the 
jaw (ipsilateral to the injection side) at maximal gap-
ing. These jaw problems did not interfere with chew-
ing, eating or speaking and did not require further 
treatment. Symptoms resolved spontaneously within 
1 month after injection in 2 patients, after 3 months in 
1 patient, and after 4 months in 1 patient.
One patient experienced mild symptoms of dry 
eye ipsilateral to the injection. These symptoms 
appeared 5 weeks after injection and resolved 7 weeks 
after injection and did not require any treatment.
Of the 13 observed AEs, 7 were considered to be 
secondary to the procedure (pain or swelling at the 
injection side and jaw problems) and 5 secondary to 
BTA (nasolabial fold asymmetry, diplopia, dry eye, 
and dysphagia). One of the patients developed a mild 
bilateral facial rash during the study that was not 
thought to be related to the procedure or the exper-
imental drug.
Secondary Outcomes (Efficacy).—For the efficacy 
outcomes we have analyzed data for 9 patients 
(excluding the protocol violator with no data 
available). A 2-sided Wilcoxon Signed Ranks Test 
was performed to compare the number of attacks, 
intensity, and function level at baseline and at 
weeks 5-8 after injection (see Table 5). The median 
number of attacks per day when comparing baseline 
vs weeks 5-8 was not statistically significant 
(P = .401). Four patients were treatment responders 
with at least 50% reduction in the median number of 
attacks between baseline and weeks 5-8. Two patients 
achieved full remission after the injection (patients 
5 and 10 in Table 6).
Table 6 shows the median number of attacks and 
median intensity of attacks at baseline and at weeks 
5-8 for each participant.
One can observe that the mean, but not the me-
dian, number of attacks per day at weeks 5-8 was in-
creased (Table 5). This was due to an outlier (patient 2 
in Table 6), who had a worsening of his TN.
The median intensity of attacks was significantly 
reduced from baseline (median 6, range 3.0-8.5) vs 
weeks 5-8 (median 3, range 0.0-9.0; P = .024).
The median function level when comparing base-
line vs weeks 5-8 was not statistically significant 
(P = .750).
Table 4.—Adverse Events
Adverse Events
Number of Patients
Resolved  
<4 Weeks
Resolved 
4-12 Weeks
Resolved Within 
4 Months After 
Injection
Pain or swelling 3 — —
Jaw problems 2 1 1
Nasolabial fold 
asymmetry
— — 2
Diplopia — — 1
Dry eye — 1 —
Dysphagia 1 — —
Rash 1 — —
Headache 7
All patients but 1 had a CAPS scale of 0 (no 
autonomic parasympathetic symptoms) both at base-
line and at month 3 after injection. One patient had 1 
point in the CAPS scale before injection due to mild 
conjunctival injection during attacks (he did not have 
lacrimation or other symptoms). His CAPS score 
3 months after injection was 0. This patient was a 
responder and went into full remission after treatment.
All patients had persistent concomitant pain 
at baseline with a median percentage of the day 
with concomitant persistent pain of 75% (minimum 
37.5%, maximum 100%). The Friedman test for 
repetitive measurements was statistically significant 
(P = .031) indicating reduction in concomitant per-
sistent pain after injection. Concomitant persistent 
pain at weeks 2 and 8 were significantly lower than 
Table 5.—Number of Attacks per Day, Intensity of Attacks Using a Numeric Rating Scale (NRS 0 to 10) and Functional 
Level (“How Much of Your Planned Activities for the Day did you Manage to Complete”: 1: all; 2: more than 50%; 3: less 
than 50%; 4: none)
Baseline Weeks 5-8 Weeks 5-8 vs Baseline
Number of attacks per day Median (range) 5.5 (1.0-51.5) 5.0 (0.0-225.0) P = .401
Mean ± SD 11.9 ± 15.6 28.3 ± 71.8
Intensity of attacks Median (range) 6.0 (3.0-8.5) 3.0 (0.0-9.0) P = .024
Mean ± SD 5.8 ± 2.1 3.65 ± 3
Functional level Median (range) 2.0 (1.0-3.3) 1.0 (1.0-4.0) P = .750
Mean ± SD 1.9 ± 0.81 2.0 ± 1.12
SD = standard deviation.
Table 6.—Median Number of Attacks per day and Median Intensity of Attacks at Baseline and at Weeks 5-8 for Each 
Participant
Patient
Number of Attacks per Day, 
Median (Range) Intensity of Attacks, Median (Range)
Surgical Interventions TriedBaseline Weeks 5-8 Baseline
Weeks 
5-8
Current Prophylactic 
Medication
1 5.5 (3-10) 5.0 (3-8) 6.0 (3-9) 5.0 (4-8) Carbamazepine —
2 52.5 (16-90) 225.0 (25-420) 8.0 (6-9) 9.0 (7-9) Gabapentine —
3 3.0 (2-4) 2.0 (2-4) 3.0 (3-5) 3.0 (2-4) Pregabaline —
4 2.5 (0-5) 5.0 (4-10) 3.5 (0-10) 2.0 (2-4) Carbamazepine Microvascular decompression
Glycerol rhizolysis of the trigeminal 
ganglion
5 16.0 (8-40) 0.0 (0-0) 8.5 (8-9.5) 0.0 (0-0) Paracetamol/codein —
6 13.5 (0-18) 6 (6-6) 7.0 (0-8) 6.0 (6-6) Oxcarbazepine —
7 15.0 (2-25) 6.5 (0-113) 8.5 (6.5-10) 6.3 (0-10) Pregabaline Microvascular decompression
Balloon-compression of the trigemi-
nal ganglion
8 1.0 (1-1) 1.0 (0-5) 4.0 (1-8) 1.5 (0-5) Oxcarbazepine —
9 † † † † Carbamazepine Microvascular decompression
10 2.0 (0-4) 0.0 (0-0) 4.0 (0-8) 0.0 (0-0) Oxcarbazepine —
†Patient number 9 was none compliant with the headache diary and was considered a protocol violator.
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at baseline (P  =  .027 and P  =  .023, respectively). 
These inferences were not statistically significant 
after proper adjustment for multiplicity. The me-
dian percentage of the day with concomitant per-
sistent pain at week 8 was 18.75% (minimum 0%, 
maximum 100%).
One patient had a PGIC of “very much im-
proved,” 2 patients “much improved,” 2 patients 
“minimally improved,” 2 “no change,” 3 “minimally 
worse (none “much worse” or “very much worse”) 
after injection.
The pain inflicted upon the patient during the in-
jection was reported on an NRS from 0 to 10 imme-
diately after injection. The mean pain reported was 
2 (range 0-2). One out of 10 patients had to use ad-
ditional analgesics on the day of the injection. Eight 
out of 10 patients in this study would recommend this 
treatment to other patients with TN.
DISCUSSION
In this paper, we have shown that injections of 
BTA toward the SPG in patients with TN, using a new 
navigation tool (the MultiGuide®), is safe. No serious 
AEs were reported in these 10 patients. All AEs re-
mitted at the latest 4 months after the treatment as 
one would expect with BTA. The main efficacy out-
come in this study was negative with median of 5.5 
attacks per day in the baseline period vs 5.0 (P = .401) 
in weeks 5-8. Four patients were treatment respond-
ers with at least 50% reduction in the median num-
ber of attacks between baseline and weeks 5-8. Two 
patients had a complete remission after the injection 
and  experienced a recurrence of attacks 1 month after 
the study end.
Patients with TN who do not have a satisfactory 
response to pharmacological treatment are often re-
ferred for surgical treatment. Quality evidence for 
efficacy of most neurosurgical procedures for TN 
has been reported to be very low because of the poor 
quality of the trials.26 TN incidence increases with 
age27 and affects a population group with high prev-
alence of comorbidities. Surgical interventions for TN 
have been reported to be highly effective but they also 
have a high risk for permanent and severe AEs. Up to 
10% of  patients undergoing a microvascular compres-
sion experience severe perioperative complications.28  
Taha et al have published a review on several percu-
taneous techniques used in TN and the prevalence of 
side effects observed in different studies28,29). Newer 
publications examining these techniques have found 
similar complication rates.30 Tuleasca et al have sum-
marized the effects of repeat Gamma Knife treatment 
for TN and found that between 11 and 80% of the 
patients develop trigeminal hypesthesia.31 The main 
concern of the percutaneous techniques are the feared 
risk of anesthesia of the cornea and anesthesia dolo-
rosa, in addition to high risk of hypoesthesia. These 
complications are typically permanent while the effect 
of the treatment is temporary. The risk for side effects 
in a non-negligible percentage of patients undergoing 
surgical procedures and the increasing prevalence with 
age underlines the need for novel, minimally invasive 
and well tolerated approaches. The AEs of the tech-
nique used in this study appears to offer a favorable AE 
profile with mostly mild and transient AEs and with no 
severe AEs reported. These results are similar to ear-
lier reports by our group in 2 other pilot trials.23,24
The role of the SPG in TN has not been estab-
lished but several authors have tried to target this 
structure.11-13,15-22,32 This study was negative for the 
main efficacy endpoint (reduction of the number of 
attacks), but there are several aspects to consider. 
Four of the 9 subjects were treatment responders. Two 
patients had a complete remission starting the day fol-
lowing the injection. This remission was sustained for 
at least 1 month after completion of the study. None 
of these 2 patients had experienced a similar sponta-
neous remission previously to the study treatment. In 
addition, a statistically significant reduction in the in-
tensity of the attacks and concomitant persistent pain 
was observed. Concomitant persistent pain in patients 
with TN has not been properly studied nor regarded 
as an endpoint in clinical trials in TN. ICHD-3 de-
scribes a subgroup of classical TN with concomitant 
continuous or near-continuous pain between attacks 
in the affected trigeminal distribution.1 Concomitant 
persistent pain has been reported in up to 49% of pa-
tients with TN.6 The 2 patients who went into full re-
mission also experienced a complete disappearance of 
their concomitant persistent pain.
Central pain mechanisms have been invoked 
in the pathophysiology of TN.3,4 Lesions induced 
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in the spinal trigeminal nucleus, but not in the tri-
geminal ganglion, of cats or rats produce a marked 
overreaction to tactile stimulation of the face and the 
occurrence of spontaneous paroxysms of pain also 
suggesting a central involvement.3 The refractory 
period observed in most patients with TN suggests 
involvement of the central nervous system.3,5 In 
patients with TN and concomitant continuous or 
near-continuous facial pain, central facilitation of 
trigeminal nociceptive processing, most likely at a 
supraspinal level, has been demonstrated. This may 
be an underlying mechanism for development of 
continuous facial pain due to overactivation of cen-
tral sensory transmission.4 The mechanism by which 
concomitant persistent pain was reduced in this study 
could either relate to a role of the SPG in pain sensi-
tization,9 placebo effect, or regression to the mean. 
Blockade of the SPG may produce a reduction in 
parasympathetic outflow and thus reduced the activa-
tion/sensitization of the intracranial nociceptors and 
central nociceptive neurons in the spinal trigeminal 
nucleus, which could theoretically reduce the inten-
sity of attacks and concomitant persistent pain, but 
not the number of attacks, as observed in this pilot 
trial. In a series of 158 prospective patients with TN, 
48 patients (31%) had autonomic symptoms, the re-
corded symptoms included conjunctival injection/
tearing (22%) and running/clogged nose (16%).6 All 
patients but 1 had a CAPS scale of 0 (no autonomic 
parasympathetic symptoms) during the baseline 
phase in the present study. The single patient whose 
CAPS score was  reduced to zero 3 months after in-
jection also experienced complete remission of pain. 
The presence of cranial parasympathetic symptoms 
may be a marker that predicts response and the low 
prevalence of patients with cranial parasympathetic 
symptoms in this study population may have nega-
tively affected the efficacy outcomes.
Limitations of the Study.—This was a small open-
label study. The placebo response in a previous 
study were patients with TN were randomized to 
a multi-point injection (between the epidermis and 
dermis) of either 25 IU of BTA, 75 IU of BTA or 
placebo was 32.1%.33 The reduction of intensity in 
attacks and reduction in the percentage of the day 
with concomitant persistent pain observed in this 
study might have been due to placebo effect. It 
has also been documented that regression to the 
mean and periods of remission may bias the results 
in uncontrolled studies.34
CONCLUSION
Injection of botulinum toxin toward the SPG 
using the novel MultiGuide® system in patients with 
TN appears to have an acceptable adverse event pro-
file as has been shown in other studies using the same 
technique.23,24
The main efficacy endpoint in this study (reduc-
tion in number of attacks) was negative, but a sig-
nificant reduction in the intensity of the attacks and 
concomitant persistent pain was observed. There 
were 4 patients with at least 50% reduction in the 
median number of attacks between baseline and 
weeks 5-8, and 2 patients experienced complete remis-
sion of pain after the injection.
This study does not give any indication for effect 
in reducing the number of TN attacks after injection 
of 25 IU of BTA toward the SPG. Further studies 
 examining the role of the SPG as a therapeutic target 
for TN are necessary.
CLINICAL IMPLICATIONS
• The injection of onabotulinum toxin A toward the 
SPG in TN appears to be safe.
• This study does not give any indication for effect in 
reducing the number of TN attacks after injection 
of 25 IU of BTA toward the SPG.
• There were 4 patients with at least 50% reduction in 
the median number of attacks between baseline and 
weeks 5-8, and 2 patients had complete remission of 
pain after the injection.
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